Pulmonary Artery Pressure in COVID-19 Survivors
Pulmonary Hypertension Secondary
About this trial
This is an interventional diagnostic trial for Pulmonary Hypertension Secondary focused on measuring pulmonary artery pressure, COVID-19 survivors, right heart catheterization
Eligibility Criteria
Inclusion Criteria: COVID-19 survivors from a moderate/severe COVID-19 pulmonary infection according to WHO COVID-19 clinical severity classification , ≥ 18 years, with residual symptoms and signs suggestive of pulmonary hypertension and not explained by other condition. Exclusion Criteria: Previous diseases that could explain the existence of PH e.g. cardiovascular, pulmonary diseases or history of pulmonary thromboembolism. Hemodynamic instability. Absolute contraindications to RHC placement include: Infection at the insertion site. The presence of a right ventricular assist device. Insertion during cardiopulmonary bypass. Lack of consent. Relative contraindications to RHC placement include: Coagulopathy (INR >1.5), thrombocytopenia (platelet count <50,000/microL). Electrolyte disturbances. Severe acid-base disturbances.
Sites / Locations
- faculty of medicine Mansoura university
Arms of the Study
Arm 1
Experimental
assess pulmonary hemodynamics in COVID-19 survivors
COVID-19 survivors from a moderate/severe COVID-19 pulmonary infection according to WHO COVID-19 clinical severity classification, ≥ 18 years, with residual symptoms and signs suggestive of pulmonary hypertension and not explained by other condition